KNTE — Kinnate Biopharma Income Statement
0.000.00%
Last trade - 00:00
- $125.62m
- -$28.41m
- 28
- 38
- 57
- 35
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 12 | 36 | 90.1 | 119 | 121 |
Operating Profit | -12 | -36 | -90.1 | -119 | -121 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -12 | -35.8 | -89.8 | -116 | -113 |
Net Income After Taxes | -12 | -35.8 | -89.8 | -116 | -113 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -12 | -35.8 | -89.8 | -116 | -113 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -9.94 | -35.8 | -89.8 | -116 | -113 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.273 | -0.823 | -2.06 | -2.64 | -2.37 |
Dividends per Share |